[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
[2] Li Z, Xue J, Chen P. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29(1):42–51. https://doi.org/10.1111/jgh.12428.
[3] Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901-10.
[4] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-44.
[5] Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646–50.
[6] Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, et al. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease. Endocrinol Metab (Seoul). 2016;31:86-92.
[7] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with
nonalcoholic fatty liver disease. N Engl J Med. 2010; 363: 1341–50.
[8] Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, Yang Y, Yu X. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017 Jan 19;16(1):15. doi: 10.1186/s12944-017-0409-6. PMID: 28103934; PMCID: PMC5248473.
[9] Simental-Mendia LE, Simental-Mendia E, Rodriguez-Hernandez H, Rodriguez-
Moran M, Guerrero-Romero F. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women. Ann Hepatol. 2016;15:715–20.
[10] Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22. doi: 10.1111/apt.12963. Epub 2014 Sep 29. PMID: 25267215.
[11] Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, Peng Y. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019 Feb 2;18(1):39. doi: 10.1186/s12944-019-0986-7. PMID: 30711017; PMCID: PMC6359827.
[12] Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A,Kato T, Kojima T, Fukui M. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 2016;36:713–20.
[13] Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardo CV, Chiesa C. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014;24:737–43.
[14] Chen Z, Qin H, Qiu S, Chen G, Chen Y. Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids Health Dis. 2019 Aug 9;18(1):162. doi: 10.1186/s12944-019-1104-6. PMID: 31399032; PMCID: PMC6689160.
[15] Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.
[16] National Workshop on Fatty Liver and Alcoholic Liver Disease CSoH, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. Zhonghua Gan Zang Bing Za Zhi. 2018;26:195-203.
[17] Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis. 2018 Nov 20;17(1):262. doi: 10.1186/s12944-018-0913-3. PMID: 30458848; PMCID: PMC6247753.
[18] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-
alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.
https://doi.org/10.1016/j.metabol.2015.12.012.
[19] Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713-23.
[20] Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005;17:823-6.
[21] Samuel VT, Liu ZX, Qu X. Mechanism of hepatic insulin resistance in non-
alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345–53. https://doi.
org/10.1074/jbc.M313478200.
[22] Kim JS, Kang HT, Shim JY, Lee HR. The association between the triglyceride to high-density lipoprotein cholesterol ratio with insulin resistance (HOMA-IR) in the general Korean population: based on the National Health and nutrition examination survey in 2007-2009. Diabetes Res Clin Pract. 2012;97:132–8.
[23] Zhou M, Zhu L, Cui X, Feng L, Zhao X, He S, Ping F, Li W, Li Y. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance but not of beta cell function in a Chinese population with different glucose tolerance status. Lipids Health Dis. 2016;15:104.
[24] Ren X, Chen ZA, Zheng S, Han T, Li Y, Liu W, Hu Y. Association between triglyceride to HDL-C ratio (TG/HDL-C) and insulin resistance in Chinese patients with newly diagnosed type 2 diabetes mellitus. PLoS One. 2016;11:e0154345.
[25] Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, Guarnizo-Poma M, Lazaro-Alcantara H, Paico-Palacios S, Del Carmen Ranilla-Seguin V, Benites-Zapata VA; Insulin Resistance and Metabolic Syndrome Research Group. High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):382-388. doi: 10.1016/j.dsx.2018.10.006. Epub 2018 Oct 10. PMID: 30641729.
[26] Lee SH, Kwon HS, Park YM, et al. Predicting the development of diabetes using the product of triglycerides and glucose: the Chungju Metabolic Disease Cohort (CMC) study. PLoS ONE. 2014;9: e90430.
[27] Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez- Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347–51.
[28] Vasques AC, Novaes FS, de Oliveira Mda S, Souza JR, Ya manaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:e98-100.
[29] Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146.
[30] Er LK, Wu S, Chou HH, Hsu LA, Teng MS, Sun YC, Ko YL. Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals. PLoS One. 2016 Mar 1; 11(3): e0149731.
[31] Babic N, Valjevac A, Zaciragic A, Avdagic N, Zukic S, Hasic S. The Triglyceride/HDL Ratio and Triglyceride Glucose Index as Predictors of Glycemic Control in Patients with Diabetes Mellitus Type 2. Med Arch. 2019 Jun;73(3):163-168. doi: 10.5455/medarh.2019.73.163-168. PMID: 31404127; PMCID: PMC6643328.
[32] Ren X, Chen ZA, Zheng S, et al. Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus. PLoS One. 2016;11:e0154345.
[33] Ren XY, Shi D, Ding J, Cheng ZY, Li HY, Li JS, Pu HQ, Yang AM, He CL, Zhang JP, Ma YB, Zhang YW, Zheng TZ, Bai YN, Cheng N. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study. Lipids Health Dis. 2019 Feb 11;18(1):47. doi: 10.1186/s12944-019-0984-9. PMID: 30744645; PMCID: PMC6371543.
[34] Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96. doi: 10.1590/s0004-28032012000100015. PMID: 22481692.
[35] Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol. 2018 Jun 1;260:196-203. doi: 10.1016/j.ijcard.2017.12.069. Erratum in: Int J Cardiol. 2018 May 12;: PMID: 29622441.